THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 123 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $415 | -6.7% | 48,023 | +11.7% | 0.00% | – |
Q2 2023 | $445 | +8.0% | 42,980 | +13.4% | 0.00% | – |
Q1 2023 | $412 | -0.7% | 37,916 | +2.6% | 0.00% | – |
Q4 2022 | $415 | -99.9% | 36,968 | -54.1% | 0.00% | – |
Q3 2022 | $818,000 | +26.6% | 80,577 | +13.0% | 0.00% | – |
Q2 2022 | $646,000 | +48.8% | 71,313 | +57.0% | 0.00% | – |
Q1 2022 | $434,000 | -4.4% | 45,408 | +10.6% | 0.00% | – |
Q4 2021 | $454,000 | +21.4% | 41,061 | -18.8% | 0.00% | – |
Q3 2021 | $374,000 | -28.1% | 50,561 | +41.1% | 0.00% | – |
Q2 2021 | $520,000 | -32.6% | 35,837 | -5.1% | 0.00% | – |
Q1 2021 | $771,000 | -90.3% | 37,774 | -91.5% | 0.00% | -100.0% |
Q4 2020 | $7,933,000 | -1.4% | 446,451 | -18.0% | 0.00% | 0.0% |
Q3 2020 | $8,049,000 | -26.9% | 544,380 | +3.8% | 0.00% | 0.0% |
Q2 2020 | $11,008,000 | -7.4% | 524,461 | +1.9% | 0.00% | -50.0% |
Q1 2020 | $11,889,000 | -12.8% | 514,469 | -2.3% | 0.00% | 0.0% |
Q4 2019 | $13,629,000 | +33.5% | 526,438 | +0.5% | 0.00% | +100.0% |
Q3 2019 | $10,208,000 | -45.1% | 524,014 | -54.0% | 0.00% | -66.7% |
Q2 2019 | $18,606,000 | -32.2% | 1,139,370 | -5.9% | 0.00% | -25.0% |
Q1 2019 | $27,453,000 | -13.0% | 1,210,979 | -1.8% | 0.00% | -20.0% |
Q4 2018 | $31,554,000 | -39.5% | 1,233,062 | -22.7% | 0.01% | -37.5% |
Q3 2018 | $52,147,000 | +32.1% | 1,596,187 | -8.3% | 0.01% | +33.3% |
Q2 2018 | $39,481,000 | -30.6% | 1,740,780 | -25.8% | 0.01% | -33.3% |
Q1 2018 | $56,871,000 | -11.9% | 2,345,195 | +1.3% | 0.01% | -10.0% |
Q4 2017 | $64,580,000 | -18.0% | 2,315,540 | +0.7% | 0.01% | -23.1% |
Q3 2017 | $78,762,000 | +49.8% | 2,300,296 | +74.3% | 0.01% | +44.4% |
Q2 2017 | $52,567,000 | +293.6% | 1,319,441 | +263.7% | 0.01% | +200.0% |
Q1 2017 | $13,356,000 | +45.3% | 362,735 | +25.8% | 0.00% | +50.0% |
Q4 2016 | $9,193,000 | -19.6% | 288,365 | -8.5% | 0.00% | 0.0% |
Q3 2016 | $11,427,000 | +139.0% | 315,323 | +49.6% | 0.00% | +100.0% |
Q2 2016 | $4,782,000 | +105.9% | 210,763 | +70.6% | 0.00% | – |
Q1 2016 | $2,323,000 | +3.9% | 123,563 | -9.4% | 0.00% | – |
Q4 2015 | $2,235,000 | +45.0% | 136,353 | -2.7% | 0.00% | – |
Q3 2015 | $1,541,000 | -5.1% | 140,175 | +12.4% | 0.00% | – |
Q2 2015 | $1,623,000 | -24.5% | 124,685 | +0.6% | 0.00% | – |
Q1 2015 | $2,151,000 | -58.0% | 123,985 | -63.8% | 0.00% | -100.0% |
Q4 2014 | $5,117,000 | -35.7% | 342,948 | -0.6% | 0.00% | -50.0% |
Q3 2014 | $7,953,000 | +140.1% | 345,045 | +232.1% | 0.00% | +100.0% |
Q2 2014 | $3,312,000 | – | 103,896 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
King Wealth Management Group | 22,500 | $583,000 | 0.15% |
Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |